Pharmaceutical preparations comprising a combination of a long-acting inhaled steroid and a long-acting beta2 receptor agonist

By providing suspension or suspension forms of long-acting inhaled steroids and β2 receptor agonists, the problem that existing dry powders cannot meet the needs of severe and severe patients is solved, and the stability and dispersion are improved. Provides treatment options for once a day.

CN115381774BActive Publication Date: 2024-11-22LEXENPHARM (SUZHOU) LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211044167.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-30
Publication Date
2024-11-22
Estimated Expiration
2042-08-30

AI Technical Summary

Technical Problem

The existing combination drugs of long-acting inhaled steroids and long-acting β2 receptor agonist are mostly dry powder inhaled drugs, which cannot meet the clinical needs of patients with severe and extremely severe asthma and COPD, and are especially unable to replace portable such as dry powder, quantitative spray and Soft mist.

Method used

Provided is a suspension or suspension dosage form containing a long-acting inhaled steroid and a long-acting β2 receptor agonist, using fluticasone furoate and vilanterol triphenyl acetate, odaterol hydrochloride or maleic acid Indaterol and other ingredients can improve the stability and dispersion of the preparation by reasonably controlling the particle size and pH of the drug ingredients, and are suitable for use once a day.

Benefits of technology

It has achieved a treatment plan for patients who cannot use portable inhaled drugs, which improves the stability and dispersion of drugs, meets the clinical needs of severe and extremely severe patients, and provides a sustainable treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115381774B_ABST
    Figure CN115381774B_ABST
Patent Text Reader

Abstract

The present application discloses a pharmaceutical preparation comprising a combination of a long-acting inhaled steroid and a long-acting β2 receptor agonist, and relates to the technical field of pharmaceutical preparations. The long-acting inhaled steroid drug is selected from fluticasone, or a pharmaceutically acceptable salt; the β2 receptor agonist is selected from vilanterol, olodaterol, indacaterol, or any pharmaceutically acceptable salt, isomer or hydrate thereof; the dosage form of the pharmaceutical preparation is a suspension or a co-mixed suspension. The present application significantly improves the stability of the prepared pharmaceutical preparation by controlling the types of pharmaceutical excipients and the preparation method. In addition, the present application also discloses the use of the pharmaceutical preparation in the preparation of an inhaled pharmaceutical composition for preventing or treating respiratory diseases such as asthma and chronic obstructive pulmonary disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of pharmaceutical preparations, and in particular to a pharmaceutical preparation comprising a combination of a long-acting inhaled steroid and a long-acting β2 receptor agonist. Background Art

[0002] Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease with a large number of patients and a high mortality rate, which affects people's health and brings a heavy economic burden to society. COPD is mainly manifested by airflow limitation that is not fully reversible. The condition usually gradually worsens and is related to the abnormal inflammatory response of lung tissue to harmful particles or harmful gases. Due to the high frequency of inhalation and the complexity of the device, treatment compliance has become a common medical problem for patients with COPD and asthma. Therefore, a new generation of long-acting beta-agonists (LABA) that can take effect quickly and have a bronchodilator effect that can last for 24 hours is expected to improve treatment compliance.

[0003] Currently, therapies to treat or prevent COPD and asthma include the use of long-acting bronchodilators or one or more inhaled corticosteroids (ICS).

[0004] Inhaled bronchodilators are the cornerstone of COPD and asthma therapy because they relieve symptoms, reduce exacerbations, and improve quality of life. These drugs also improve airflow limitation and hyperinflation, thereby reducing respiratory effort and improving exercise tolerance. Furthermore, bronchodilators can reduce respiratory muscle fatigue and improve mucociliary clearance.

[0005] Bronchodilators include beta 2 agonists, which may be short-acting for immediate relief of asthma symptoms, or long-acting for long-term prevention of asthma symptoms.

[0006] Long-acting β2 agonists (LABA) or ultra-long-acting β2 agonists (ULABA) can improve lung function, reduce symptoms, and prevent exercise-induced dyspnea in patients with asthma and COPD. LABA causes bronchodilation by causing prolonged relaxation of airway smooth muscle. Secondly, LABA also plays other roles, such as inhibiting airway smooth muscle cell proliferation and inflammatory mediator release, as well as non-smooth muscle effects, such as stimulating mucociliary transport function, cell protection of respiratory mucosa, and weakening neutrophil recruitment and activation.

[0007] In addition, the use of LABA can reduce the frequency of drug administration. Commercially available twice-daily LABAs include salmeterol, formoterol, and aformoterol; commercially available once-daily ultra-long-acting β2 agonists ULABAs include indacaterol, vilanterol, carmoterol, and olodaterol.

[0008] Although beta2 agonists and anticholinergics provide symptomatic relief of bronchoconstriction, another element of COPD as inflammation requires separate treatment with steroids, most inhaled corticosteroids need to be administered in a multiple dosing regimen.

[0009] Corticosteroids show inhibitory effects on inflammatory cells and inflammatory mediators involved in the pathology of respiratory disorders such as COPD. Treatment with corticosteroids / glucocorticoids is considered to be one of the most potent and effective therapies currently available for COPD.

[0010] There are currently several commercially available pharmaceutical compositions for inhalation that include a combination of a LABA and an inhaled corticosteroid (ICS). An example of a pharmaceutical combination used to treat asthma and chronic obstructive pulmonary disease (COPD) is salmeterol / fluticasone propionate ( diskus and HFA) and formoterol fumarate dihydrate / budesonide (Symbicort); formoterol and mometasone (Dulera); salmeterol / fluticasone furoate (AirDuo TM ); vilanterol, fluticasone furoate Dry powder dosage form (DPI) and aerosol dosage form (MDI).

[0011] Among them, Fluticasone Furoate has the following chemical structure:

[0012]

[0013] Fluticasone furoate is a new type of synthetic fluorinated glucocorticoid. It was approved by the US FDA in April 2007 for the treatment of seasonal and perennial allergic rhinitis. As a fast-acting and potent glucocorticoid, it has become a classic treatment for allergic rhinitis. Compared with fluticasone propionate, fluticasone furoate has a higher receptor affinity; faster transport from the glucocorticoid receptor to the nucleus and longer nuclear retention time; higher selectivity than other glucocorticoids; reduced cellular efflux and increased intracellular binding, and prolonged duration of efficacy. Compared with other glucocorticoids, fluticasone furoate has the strongest effect in maintaining epithelial integrity and reducing epithelial permeability in response to protease or mechanical cell damage.

[0014] Vilanterol Trifenatate, the chemical structure is as follows:

[0015]

[0016] Vilanterol triphenylacetate is a new type of long-acting selective β2 receptor agonist for oral inhalation. Compared with salmeterol, it has a faster onset and longer duration of action. In addition, the affinity of vilanterol triphenylacetate for β2 receptors is 1000 times higher than that for J31 receptors and β2 receptors, and it is highly selective. Clinical studies have shown that the bronchodilator effect of vilanterol triphenylacetate can last for 24 hours. Taking it once a day for 4 weeks can significantly improve the lung function of COPD patients, and it has good tolerability and safety, and the incidence of adverse reactions of LABA effects (increased blood sugar levels, hypertension, decreased blood potassium levels, tremors and palpitations) is low.

[0017] Olodaterol HCl has the following chemical structure:

[0018]

[0019] Olodaterol hydrochloride is an ultra-long-acting β2-adrenergic receptor agonist. Due to its longer half-life and once-daily administration, it is expected to improve patients' treatment compliance. Olodaterol hydrochloride was developed by Boehringer Ingel Chemicalbookheim and launched in the United States in 2014. It is a new type of selective rapid-acting LABA with high selectivity for β2-adrenergic receptors (referred to as β2-receptors), rapid onset, long half-life of more than 12 hours, and can maintain 24 hours of bronchodilator effect, so it can be taken once a day.

[0020] Indacaterol Maleate, the chemical structure is as follows:

[0021]

[0022] Indacaterol is a bronchodilator that belongs to the long-acting inhaled β2-receptor agonist (LABA) class and is suitable for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). Indacaterol has the characteristics of taking effect in 5 minutes and lasting for 24 hours. Indacaterol maleate is produced by Novartis Pharmaceuticals of Switzerland and has been marketed in more than 70 countries and regions around the world since 2009. It was approved by the State Food and Drug Administration for marketing in China in June 2012 under the trade name It is the first LABA single preparation approved in China for the treatment of COPD.

[0023] US Patent No. 11116721 B2 discloses a combination dry powder inhalation drug comprising a long-acting β2 agonist vilanterol triphenylacetate and a long-acting steroid fluticasone furoate; Chinese Patent No. CN104470503A discloses a combination dry powder inhalation drug comprising a long-acting β2 agonist vilanterol triphenylacetate and a long-acting steroid fluticasone furoate and umeclidinium bromide. Chinese Patent No. CN103501776A discloses a combination dry powder inhalation drug comprising glycopyrrolate, vilanterol and fluticasone furoate.

[0024] However, most current pharmaceutical compositions are dry powder inhalation drugs, which cannot meet the clinical needs of patients with severe and extremely severe asthma and COPD. Therefore, it is necessary to provide a treatment plan for patients who cannot use portable devices such as dry powder inhalers (DPI), metered-dose inhalers (MDI) and soft mist inhalers (SMI), and to provide an inhalation suspension containing a combination of a long-acting inhaled steroid and a long-acting β2 receptor agonist for once-daily use to treat asthma and COPD. Summary of the invention

[0025] In view of the problems existing in the prior art, one object of the present application is to provide a pharmaceutical preparation comprising a combination of a long-acting inhaled steroid and a long-acting β2 receptor agonist; the pharmaceutical preparation can be used once a day to treat asthma and COPD.

[0026] The long-acting inhaled steroid drug is selected from Fluticasone Furoate, or a pharmaceutically acceptable salt thereof;

[0027] Preferably, the long-acting inhaled steroid drug is fluticasone furoate;

[0028] The β2 receptor agonist is selected from Vilanterol, Olodaterol, Indacaterol, or any pharmaceutically acceptable salt, isomer or hydrate thereof;

[0029] Preferably, the vilanterol is in the form of vilanterol triphenylacetate; the olodaterol is in the form of olodaterol hydrochloride; the indacaterol is in the form of indacaterol maleate;

[0030] Preferably, the long-acting β2 agonist is selected from one or more of vilanterol triphenylacetate, olodaterol hydrochloride, and indacaterol maleate.

[0031] The dosage form of the pharmaceutical preparation is a suspension or a co-suspension; the pH value of the pharmaceutical preparation is 2.5-6.0.

[0032] At least 90% by volume of the active agent particles of the suspension or co-suspension have an optical diameter of 7 μm or less; at least 50% by volume of the active agent particles have an optical diameter of 5 μm or less.

[0033] As a preferred embodiment, the pharmaceutical preparation comprises a compound suspension preparation consisting of fluticasone furoate or a physiologically acceptable salt of fluticasone furoate and vilanterol;

[0034] Preferably, the pharmaceutical preparation is a nebulized inhalation mixed suspension preparation comprising vilanterol and fluticasone furoate;

[0035] The vilanterol is a vilanterol in the form of triphenylacetate dissolved in an aqueous phase;

[0036] The pharmaceutical preparation is an aerosol inhalation mixed suspension preparation containing vilanterol triphenylacetate and fluticasone furoate.

[0037] In the pharmaceutical preparation, the daily inhalation dosage of vilanterol triphenylacetate is 10-100 μg, and the daily inhalation dosage of fluticasone furoate is 25-1000 μg.

[0038] In some preferred embodiments, the nebulized inhalation suspension preparation of vilanterol triphenylacetate and fluticasone furoate further comprises sulfobutyl-β-cyclodextrin, and each ml of the liquid preparation contains 5 mg to 500 mg of sulfobutyl-β-cyclodextrin.

[0039] As another preferred embodiment, the pharmaceutical preparation comprises a compound suspension preparation consisting of fluticasone furoate or a physiologically acceptable salt of fluticasone furoate and olodaterol;

[0040] Preferably, the pharmaceutical preparation is a nebulized inhalation suspension preparation comprising olodaterol and fluticasone furoate;

[0041] The olodaterol is in the form of olodaterol hydrochloride dissolved in an aqueous phase;

[0042] The pharmaceutical preparation is an aerosol inhalation suspension preparation containing olodaterol hydrochloride and fluticasone furoate.

[0043] The daily inhalation dosage of olodaterol hydrochloride in the pharmaceutical preparation is 1-100 μg, and the daily inhalation dosage of fluticasone furoate is 25-1000 μg.

[0044] As another preferred embodiment, the pharmaceutical preparation comprises a compound suspension preparation consisting of fluticasone furoate or a physiologically acceptable salt of fluticasone furoate and indacaterol maleate;

[0045] Preferably, the pharmaceutical preparation is a nebulized inhalation mixed suspension preparation comprising indacaterol and fluticasone furoate;

[0046] The indacaterol is in the form of maleate dissolved in the aqueous phase;

[0047] The pharmaceutical preparation is an aerosol inhalation mixed suspension preparation containing indacaterol maleate and fluticasone furoate.

[0048] In the pharmaceutical preparation, the daily inhalation dosage of indacaterol maleate is 20-200 μg, and the daily inhalation dosage of fluticasone furoate is 25-500 μg.

[0049] The pharmaceutical preparation is a pharmaceutical preparation for inhalation;

[0050] The administration method of the pharmaceutical preparation is spray administration;

[0051] The pharmaceutical preparation further comprises one or more of an isotonic agent, a buffer, an excipient, a stabilizer and a chelating agent;

[0052] The isotonic agent is sodium chloride;

[0053] The buffer is citric acid or phosphate buffer;

[0054] The excipient is selected from one or more of polysorbate 20, polysorbate 80, sorbitan monolaurate, poloxamer, polyoxyethylene castor oil, polyethylene glycol, solutol HS15 and polyvinyl pyrrolidone; preferably polysorbate 80.

[0055] The stabilizer is selected from one or more of ethylenediaminetetraacetic acid, dehydrated disodium ethylenediaminetetraacetic acid, disodium ethylenediaminetetraacetic acid and citric acid; preferably ethylenediaminetetraacetic acid.

[0056] The present application also provides a method for preparing the above-mentioned pharmaceutical preparation, comprising the following steps:

[0057] (1) Add the prescribed amount of excipients to water for injection, stir and dissolve, and adjust the pH with a buffer solution to prepare a buffer solution;

[0058] (2) using a disperser to disperse the long-acting inhaled steroid raw material in the above-mentioned 10% volume buffer solution, stirring the solution with the disperser, and then adding the β2 receptor agonist raw material, and continuing to disperse the solution with the disperser to obtain a dispersion of the two raw materials;

[0059] (3) mixing the dispersions of the two raw materials with the remaining buffer solution, and dispersing in a disperser to prepare a suspension or a blended suspension;

[0060] (4) The suspension is filled into an LDPE bottle to obtain a suspension for inhalation or a blended suspension.

[0061] The present application also provides the use of the above-mentioned pharmaceutical preparation in the preparation of drugs for treating respiratory diseases, wherein the respiratory diseases include but are not limited to chronic obstructive pulmonary disease (COPD) and all types of asthma.

[0062] Compared with the prior art, the beneficial effects of this application are:

[0063] (1) Most of the pharmaceutical preparations containing a combination of a long-acting inhaled steroid and a long-acting β2 receptor agonist prepared by the prior art are dry powder inhalation drugs, which cannot meet the clinical needs of patients with severe and extremely severe asthma and COPD; the present application provides a suspension or co-mixed suspension containing a combination of a long-acting inhaled steroid and a long-acting β2 receptor agonist through creative labor, providing a treatment plan for patients who cannot use portable inhalers such as dry powder inhalers (DPI), metered-dose inhalers (MDI) and soft mist inhalers (SMI);

[0064] (2) In the implementation process of the present application, by reasonably controlling the type and amount of drug excipients, and by controlling the particle size of the drug ingredients, and controlling the pH of the drug preparation to 2.5-6.0, the stability of the prepared suspension or co-mixed suspension is significantly improved, and the single and total impurity contents in the drug preparation will not increase significantly after long-term storage or high-temperature storage, and the drug preparation has good dispersibility. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 is the particle size distribution diagram of sample 1 in test example 1;

[0066] Figure 2 is the particle size distribution diagram of sample 2 in test example 1;

[0067] Figure 3 is the particle size distribution diagram of sample 3 in test example 1;

[0068] Figure 4 This is the total impurity change diagram of fluticasone furoate-vilanterol triphenylacetate co-suspension at different pH ranges at 60°C for 10 days;

[0069] Figure 5 This is the total impurity change diagram of fluticasone furoate-vilanterol triphenylacetate-cyclodextrin suspension at different pH ranges at 60°C for 10 days;

[0070] Figure 6 This is the total impurity change diagram of fluticasone furoate-olodaterol hydrochloride suspension at different pH ranges at 60°C for 10 days;

[0071] Figure 7 This is the total impurity change diagram of fluticasone furoate-indacaterol maleate co-suspension at different pH ranges at 60℃ for 10 days. Specific embodiments

[0072] The technical solution of the present invention is further defined below in conjunction with specific implementation methods, but the scope of protection required is not limited to the description.

[0073] The raw material components used in the present invention were purchased from the following manufacturers and models:

[0074] Fluticasone furoate: Manufacturer Aurisco Batch number: A28-180801F13

[0075] Vilanterol triphenylacetate: Manufacturer: Inke Batch No.: PP-6M

[0076] Olodaterol hydrochloride: Manufacturer: Inke Batch number: PP-1

[0077] Indacaterol Maleate: Manufacturer: Inke Batch No.: P-4

[0078] The equipment used in the present invention was purchased from the following manufacturers and models:

[0079] Disperser: Manufacturer: IKA Model: T18

[0080] Microfluidizer Manufacturer: PSI Model: PSI 20

[0081] Example 1 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0082] The components of a single vial of fluticasone furoate and vilanterol suspension for inhalation and their total prescription amount are shown in the following table.

[0083] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.4mg 0.2g Edetate Disodium 0.2mg 0.1g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0084] Preparation process:

[0085] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve, and dilute to 1000 ml to prepare a buffer solution;

[0086] (2) using a disperser to disperse the fluticasone furoate raw material in the above 100 ml buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material in the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0087] (3) Mixing the API dispersion with the remaining buffer solution, and preparing a blended suspension by dispersing at 9000 rpm for 30 min;

[0088] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol mixed suspension for inhalation.

[0089] Example 2 Preparation of Fluticasone Furoate Suspension for Inhalation

[0090] The components and prescription quantities of a single vial of fluticasone furoate simple suspension for inhalation are shown in the following table.

[0091] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Polysorbate 80 0.4mg 0.2g EDTA 0.2mg 0.1g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0092] Preparation process:

[0093] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve, and dilute to 1000 ml to prepare a buffer solution;

[0094] (2) The fluticasone furoate raw material was dispersed in the above 100 ml buffer solution using a disperser, the speed of the disperser was 9000 rpm, and the dispersion time was 30 min.

[0095] (3) Mixing the API dispersion with the remaining buffer solution and preparing a suspension in a disperser at 9000 rpm for 30 min;

[0096] (4) The suspension obtained above was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate single prescription suspension for inhalation.

[0097] Example 3 Preparation of Triphenylacetate Vilanterol Single Suspension for Inhalation

[0098] The components and prescription quantities of a single vial of Vilanterol Simple Suspension for Inhalation are shown in the following table.

[0099] Components Single prescription quantity Total Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.4mg 0.2g EDTA 0.2mg 0.1g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0100] Preparation process:

[0101] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve, and dilute to 1000 ml to prepare a buffer solution;

[0102] (2) using a disperser to disperse the vilanterol triphenylacetate raw material in the above 100 ml buffer solution, the disperser speed is 9000 rpm, and the dispersion time is 30 min;

[0103] (3) Mixing the API dispersion with the remaining buffer solution and preparing a suspension in a disperser at 9000 rpm for 30 min;

[0104] (4) The suspension obtained above was filled into a 2 ml LDPE bottle to prepare a vilanterol triphenylacetate single prescription suspension for inhalation.

[0105] Test Example 1

[0106] The particle sizes of the blended suspensions and single-prescription suspensions prepared in Examples 1-3 were measured by a Synpatek laser particle size tester.

[0107] Sample 1, Sample 2 and Sample 3 are fluticasone furoate and vilanterol mixed suspension (Example 1), fluticasone furoate single suspension (Example 2), and vilanterol single suspension (Example 3), respectively, and their particle size distributions are shown in Table 1 below.

[0108] Table 1

[0109] serial number D10 D50 D90 Sample 1 0.78μm 2.14μm 4.70μm Sample 2 0.74μm 1.89μm 4.14μm Sample 3 0.53μm 1.93μm 5.39μm

[0110] Test Example 2

[0111] Preparation and stability study of fluticasone furoate, triphenylacetate and vilanterol mixed suspensions in different pH ranges

[0112] Seven groups of blended suspensions were prepared according to the prescription and preparation method in Example 1. A 0.1M citric acid-sodium citrate buffer solution with a pH of 3.0, a 0.1M citric acid-sodium citrate buffer solution with a pH of 6.6, and a 1M sodium citrate solution were prepared, and the pH of the blended suspensions was adjusted to 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 and 7.0 respectively with the above solutions, and the high temperature influence factor test (60°C for 10d) was placed to investigate the stability of the preparations under different pH ranges. The results of the investigation are shown in Table 2 below.

[0113] Table 2

[0114]

[0115]

[0116] According to the data in Table 2 above, it can be seen that the fluticasone furoate / triphenylacetate / vilanterol co-suspension has good stability at a pH of 3.5-6.0, especially when the pH is 3.5-5.0, the fluticasone furoate / triphenylacetate / vilanterol co-suspension has the best stability, low content of total impurities and maximum single impurity, and good dispersibility.

[0117] Example 4 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0118] The components and prescription quantities of a single vial of fluticasone furoate / triphenylacetate / vilanterol mixed suspension for inhalation are as follows:

[0119] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.2mg 0.1g EDTA 0.1mg 0.05g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0120] In this example, a fluticasone furoate-vilanterol triphenylacetate suspension for inhalation (pH 3.5) containing 0.005% (w / w) EDTA / 0.01% (w / w) polysorbate 80 was prepared.

[0121] The preparation method is:

[0122] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve and dilute to 1000 ml to prepare a buffer solution, and adjust the pH to 3.5 with 0.1 M citric acid-sodium citrate buffer at pH 3.0;

[0123] (2) using a disperser to disperse the fluticasone furoate raw material in the above 100 ml buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material in the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0124] (3) Mixing the API dispersion with the remaining buffer solution in a disperser at 9000 rpm for 30 min to prepare a blended suspension;

[0125] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol triphenylacetate mixed suspension for inhalation.

[0126] Example 5 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0127] The components and prescription quantities of a single vial of fluticasone furoate / triphenylacetate / vilanterol mixed suspension for inhalation are as follows:

[0128] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.2mg 0.1g EDTA 0.3mg 0.15g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0129] In this example, a fluticasone furoate-vilanterol triphenylacetate suspension for inhalation (pH 3.5) containing 0.015% (w / w) EDTA / 0.01% (w / w) polysorbate 80 was prepared.

[0130] The preparation method is:

[0131] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve and dilute to 1000 ml to prepare a buffer solution, and adjust the pH to 3.5 with 0.1 M citric acid-sodium citrate buffer at pH 3.0;

[0132] (2) using a disperser to disperse the fluticasone furoate raw material in the above 100 ml buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material in the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0133] (3) Mixing the API dispersion with the remaining buffer solution in a disperser at 9000 rpm for 30 min to prepare a blended suspension;

[0134] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol triphenylacetate mixed suspension for inhalation.

[0135] Example 6 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0136] The components and prescription quantities of a single vial of fluticasone furoate / triphenylacetate / vilanterol mixed suspension for inhalation are as follows:

[0137]

[0138]

[0139] In this example, a fluticasone furoate-vilanterol triphenylacetate suspension for inhalation (pH 3.5) containing 0.015% (w / w) EDTA / 0.03% (w / w) polysorbate 80 was prepared.

[0140] The preparation method is:

[0141] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve and dilute to 1000 ml to prepare a buffer solution, and adjust the pH to 3.5 with 0.1 M citric acid-sodium citrate buffer at pH 3.0;

[0142] (2) using a disperser to disperse the fluticasone furoate raw material in the above 100 ml buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material in the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0143] (3) Mixing the API dispersion with the remaining buffer solution in a disperser at 9000 rpm for 30 min to prepare a blended suspension;

[0144] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol triphenylacetate mixed suspension for inhalation.

[0145] Example 7 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0146] The components and prescription quantities of a single vial of fluticasone furoate / triphenylacetate / vilanterol mixed suspension for inhalation are as follows:

[0147] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.2mg 0.1g EDTA 0.1mg 0.05g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0148] In this example, a 0.005% (w / w) EDTA / 0.01% (w / w) polysorbate 80 fluticasone furoate-vilanterol triphenylacetate suspension for inhalation (pH 6.5) was prepared.

[0149] Preparation method:

[0150] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve and dilute to 1000 ml to prepare a buffer solution, and adjust the pH to 6.5 with 0.1 M citric acid-sodium citrate buffer solution with a pH of 6.6;

[0151] (2) using a disperser to disperse the fluticasone furoate raw material in 100 ml of a buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material by the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0152] (3) Mixing the API dispersion with the remaining buffer solution, and preparing a blended suspension by dispersing at 9000 rpm for 30 min;

[0153] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol triphenylacetate mixed suspension for inhalation.

[0154] Example 8 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0155] The components and prescription quantities of a single vial of fluticasone furoate / triphenylacetate / vilanterol mixed suspension for inhalation are as follows:

[0156] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.2mg 0.1g EDTA 0.3mg 0.15g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0157] In this example, a fluticasone furoate-vilanterol triphenylacetate suspension for inhalation (pH 6.5) containing 0.015% (w / w) EDTA / 0.01% (w / w) polysorbate 80 was prepared.

[0158] Preparation method:

[0159] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve and dilute to 1000 ml to prepare a buffer solution, and adjust the pH to 6.5 with 0.1 M citric acid-sodium citrate buffer solution with a pH of 6.6;

[0160] (2) using a disperser to disperse the fluticasone furoate raw material in 100 ml of a buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material by the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0161] (3) Mixing the API dispersion with the remaining buffer solution in a disperser at 9000 rpm for 30 min to prepare a blended suspension;

[0162] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol triphenylacetate mixed suspension for inhalation.

[0163] Example 9 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0164] The components and prescription quantities of a single vial of fluticasone furoate / triphenylacetate / vilanterol mixed suspension for inhalation are as follows:

[0165] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.6mg 0.3g EDTA 0.3mg 0.15g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0166] In this example, a fluticasone furoate-vilanterol triphenylacetate suspension for inhalation (pH 6.5) of 0.015% (w / w) EDTA / 0.03% (w / w) polysorbate 80 was prepared.

[0167] Preparation method:

[0168] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve and dilute to 1000 ml to prepare a buffer solution, and adjust the pH to 6.5 with 0.1 M citric acid-sodium citrate buffer solution with a pH of 6.6;

[0169] (2) using a disperser to disperse the fluticasone furoate raw material in the above 100 ml buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material in the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0170] (3) Mixing the API dispersion with the remaining buffer solution in a disperser at 9000 rpm for 30 min to prepare a blended suspension;

[0171] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol triphenylacetate mixed suspension for inhalation.

[0172] Example 10 Fluticasone furoate-vilanterol triphenylacetate mixed suspension for inhalation and its preparation method

[0173] The components and prescription quantities of a single vial of fluticasone furoate / triphenylacetate / vilanterol mixed suspension for inhalation are as follows:

[0174] Components Single prescription quantity Total Fluticasone furoate API 0.17mg 0.085g Vilanterol triphenylacetate API 0.068mg 0.034g Polysorbate 80 0.4mg 0.2g EDTA 0.2mg 0.1g Sodium chloride 17mg 8.5g Water for injection Add to 2ml Add to 1000ml

[0175] In this example, a fluticasone furoate-vilanterol triphenylacetate suspension for inhalation (pH 5.0) of 0.01% (w / w) EDTA / 0.02% (w / w) polysorbate 80 was prepared.

[0176] Preparation method:

[0177] (1) Add the prescribed amount of excipients to 800 ml of water for injection, stir to dissolve and dilute to 1000 ml to prepare a buffer solution, and adjust the pH to 5.0 with 0.1 M citric acid-sodium citrate buffer solution at pH 6.6;

[0178] (2) using a disperser to disperse the fluticasone furoate raw material in 100 ml of a buffer solution at a disperser speed of 9000 rpm for 30 min, then adding the vilanterol triphenylacetate raw material, and continuing to disperse the raw material by the disperser at 9000 rpm for 30 min to obtain a dispersion of the two raw materials;

[0179] (3) Mixing the API dispersion with the remaining buffer solution, and preparing a blended suspension by dispersing at 9000 rpm for 30 min;

[0180] (4) The above suspension was filled into a 2 ml LDPE bottle to prepare a fluticasone furoate / vilanterol triphenylacetate mixed suspension for inhalation.

[0181] Test Example 3

[0182] Comparison of stability of related substances in co-mixed suspensions prepared at different pH and EDTA dosages

[0183] The samples prepared in the above Examples 4-10 were placed at 60°C for 10 days for a high temperature influence factor test, and the stability of the samples was compared based on the results of the relevant substances in the influence factor test, as shown in Table 3 below.

[0184] Table 3

[0185]

[0186] According to the test data in Table 3 above, it can be seen that the pH value has a great influence on the stability of the fluticasone furoate, triphenylacetate and vilanterol co-suspension. When the pH is 6.5, the high temperature stability of the triphenylacetate and vilanterol component in the fluticasone furoate, triphenylacetate and vilanterol co-suspension is significantly weakened, and the impurity content is significantly increased. Therefore, the pH value range of the fluticasone furoate, triphenylacetate and vilanterol co-suspension is optimal at 3.5-5.0, which is consistent with the conclusion of Test Example 2, and it is determined that the EDTA dosage is (0.015% w / w), and the polysorbate 80 dosage is 0.01% (0.01% w / w) The stability of the co-suspension is the best.

[0187] Test Example 4 Comparison of Related Substances before and after Sterilization of API

[0188] In this test example, a series of experiments were conducted to clarify the effects of sterilization temperature and time on the related substances of fluticasone furoate and vilanterol raw materials.

[0189] Fluticasone furoate and vilanterol triphenylacetate were treated for a certain period of time by wet heat sterilization and dry heat sterilization, respectively. Sample 1 was sterilized by wet heat sterilization at 120°C × 8 min, sample 2 was sterilized by wet heat sterilization at 121°C × 15 min, sample 3 was sterilized by dry heat sterilization at 110°C × 2 h, and sample 4 was sterilized by dry heat sterilization at 120°C × 2 h. After sterilization, the relevant substances of each group of samples were analyzed, as shown in Table 4.

[0190] Table 4

[0191]

[0192]

[0193] According to the test results in Table 4 above, it can be seen that both fluticasone furoate and vilanterol triphenylacetate APIs are not resistant to wet heat sterilization. However, fluticasone furoate can withstand dry heat sterilization at 120°C for 2 hours, and although the total impurities and the maximum single impurity of vilanterol triphenylacetate increased after 110°C for 2 hours, they were within the acceptable range. Test Example 5 Preparation and Stability Study of API Co-mixed Suspension after Dry Heat Sterilization

[0194] Test Example 4 shows that fluticasone furoate can withstand dry heat sterilization, and the related substances of vilanterol triphenylacetate partially increase after dry heat sterilization. The related substances of fluticasone furoate and vilanterol triphenylacetate prepared as a mixed suspension of the sterilized raw materials are analyzed, and the stability of different pH ranges (3.5, 4.0, 4.5, 5.0) is again examined for 1 month acceleration and 10 days at high temperature using the determined EDTA dosage (0.015%) and polysorbate 80 dosage (0.01%). The results are shown in Table 5 below.

[0195] Table 5

[0196]

[0197] According to Table 5 and Figure 4 It can be seen from the test data that fluticasone furoate has good stability in the pH range of 3.5-5.0, while the total impurity content of vilanterol triphenylacetate is already high at 0 day, and the total impurity content increases significantly after being placed at 60°C for 10 days when the pH is in the range of 4.5-5.0, indicating that the optimal pH value of vilanterol triphenylacetate is 3.5-4.0.

[0198] Example 11 Preparation of Vilanterol Triphenylacetate-Cyclodextrin Inhalation Solution (0.5% Cyclodextrin)

[0199] Weigh 0.075g EDTA, 4.25g Nacl and 0.05g polysorbate 80, add to water for injection and settle to 500ml, prepare buffer, measure 50ml buffer, add 2.5g sulfobutyl-β-cyclodextrin to disperse and dissolve, weigh 17mg triphenylacetate vilanterol bulk drug and add to the above solution, disperse 30min with disperser 9000rpm, obtain triphenylacetate vilanterol clear solution, disperse the solution with remaining 450ml buffer under disperser 9000rpm for 30min to fully mix, the solution remains clear without precipitation. The solution is filtered through 0.45+0.22μm PVDF needle filter (manufacturer: Cobetter model: SFM25DLHPVND4522P) to obtain triphenylacetate vilanterol inhalation solution.

[0200] Example 12 Preparation of Vilanterol Triphenylacetate-Cyclodextrin Inhalation Solution (1.5% Cyclodextrin)

[0201] Weigh 0.075g EDTA, 4.25g Nacl and 0.05g polysorbate 80, add to water for injection and settle to 500ml, prepare buffer, measure 150ml buffer, add 7.5g sulfobutyl-β-cyclodextrin to disperse and dissolve, weigh 17mg triphenylacetate vilanterol bulk drug and add to the above solution, disperse 30min with disperser 9000rpm, obtain triphenylacetate vilanterol clear solution, disperse the solution with remaining 350ml buffer under disperser 9000rpm for 30min to fully mix, the solution remains clear without precipitation. The solution is filtered through 0.45+0.22μm PVDF needle filter (manufacturer: Cobetter model: SFM25DLHPVND4522P) to obtain triphenylacetate vilanterol inhalation solution.

[0202] Example 13 Preparation of Fluticasone Furoate-Vilanterol Triphenylacetate-Cyclodextrin Suspension for Inhalation

[0203] Weigh 0.075 g EDTA, 4.25 g Nacl and 0.05 g polysorbate 80, add them to water for injection and dilute to 500 ml to prepare a buffer solution, measure 150 ml of the buffer solution, add 7.5 g of sulfobutyl-β-cyclodextrin to disperse and dissolve, weigh 17 mg of vilanterol triphenylacetate bulk drug, disperse it with a disperser at 9000 rpm for 30 min, and filter it through a 0.45 + 0.22 μm PVDF syringe filter (manufacturer: Cobetter model: SFM25DLHPVND4522P) to obtain a clear solution of vilanterol triphenylacetate.

[0204] Then 50 ml of buffer solution was measured, 42.5 mg of fluticasone furoate API was weighed and added, and dispersed in a disperser at 9000 rpm for 30 min to obtain a fluticasone furoate suspension. The fluticasone furoate suspension was dispersed in a disperser at 9000 rpm for 30 min with the vilanterol triphenylacetate solution and the remaining buffer solution to obtain a fluticasone furoate-vilanterol-cyclodextrin suspension for inhalation.

[0205] Test Example 6 Comparison of the stability of vilanterol triphenylacetate single suspension and vilanterol triphenylacetate-cyclodextrin inhalation solution

[0206] 0.075 g EDTA, 4.25 g NaCl and 0.05 g polysorbate 80 were weighed and added to water for injection and the volume was adjusted to 500 ml to prepare a buffer solution. 50 ml of the buffer solution was measured, 17 mg of the vilanterol triphenylacetate bulk drug was weighed and added to the above solution, and the vilanterol triphenylacetate dispersion was obtained by dispersing at 9000 rpm for 30 min in a disperser to obtain the vilanterol triphenylacetate dispersion, and the dispersion was dispersed with the remaining 450 ml of the buffer solution in a disperser at 9000 rpm for 30 min to be fully mixed to obtain a vilanterol triphenylacetate single prescription suspension.

[0207] The vilanterol triphenylacetate-cyclodextrin inhalation solution was prepared according to the prescription and process of Example 11, and the stability of the two was compared based on the content and related substances under high temperature influence factors. The results are shown in Table 6.

[0208] Table 6

[0209]

[0210] According to the test data in Table 6 above, it can be seen that compared with the single suspension of vilanterol triphenylacetate, the inhalation solution prepared by mixing sulfobutyl-β-cyclodextrin and vilanterol triphenylacetate in Example 11 has better stability at 60°C for 10 days, and its content and related substances are more stable.

[0211] Test Example 7 Comparison of related substances in the stability of fluticasone furoate-vilanterol triphenylacetate-cyclodextrin suspensions at different pH

[0212] A 0.1 M citric acid-sodium citrate buffer solution with a pH of 3.0 and a 0.1 M citric acid-sodium citrate buffer solution with a pH of 6.6 were prepared. The pH of the fluticasone furoate-vilanterol triphenylacetate-cyclodextrin suspension prepared in Example 13 was adjusted to 3.5, 4.0, 4.5, 5.0 and 5.5, respectively, using the buffer solution. The suspension was placed in a high temperature influence factor test (60° C. for 10 d) to investigate the stability of the preparations in different pH ranges. The results of the investigation are shown in Table 7.

[0213] Table 7

[0214]

[0215] According to Table 7 and Figure 5 It can be seen from the test data that when the pH is 3.5, the total impurity content of vilanterol at 60°C for 10 days increases significantly, and when the pH is 5.5, the total impurity content of vilanterol triphenylacetate increases significantly at 60°C for 10 days. Therefore, it is concluded that the appropriate pH value of the fluticasone furoate-vilanterol triphenylacetate-cyclodextrin mixed suspension is 4.0-5.0.

[0216] Example 14 Preparation of Fluticasone Furoate-Olodaterol Hydrochloride Suspension for Inhalation

[0217] 0.075 g EDTA, 4.25 g NaCl and 0.05 g polysorbate 80 were weighed and added to water for injection and the volume was fixed to 500 ml to prepare a buffer solution. 50 ml of the buffer solution was measured, 42.5 mg of fluticasone furoate raw material was weighed and added, and dispersed in a disperser at 9000 rpm for 30 min to obtain a fluticasone furoate suspension.

[0218] 34.2 mg of olodaterol hydrochloride bulk drug was weighed and added to the remaining buffer solution, and stirred at 300 rpm for 30 min by magnetic stirring to obtain a clear olodaterol hydrochloride solution. The fluticasone furoate suspension and the olodaterol hydrochloride solution were dispersed by a disperser at 9000 rpm for 30 min to be fully mixed to obtain a fluticasone furoate-olodaterol hydrochloride suspension for inhalation.

[0219] Test Example 8 Comparison of related substances in the stability of fluticasone furoate-olodaterol hydrochloride suspensions at different pH

[0220] 0.1 M citric acid-sodium citrate buffer with a pH of 3.0, 0.1 M citric acid-sodium citrate buffer with a pH of 6.6, and 1 M citric acid solution were prepared. The pH of the fluticasone furoate-olodaterol hydrochloride suspension was adjusted to 2.5, 3.0, 3.5, 4.0, 4.5, 5.0 and 5.5, respectively, using the above three solutions. The high temperature influence factor test (60°C for 10 days) was carried out to investigate the stability of the preparations in different pH ranges. The results of the investigation are shown in Table 8.

[0221] Table 8

[0222]

[0223] According to Table 8 and Figure 6 It can be seen from the test data that the suspension formed by olodaterol hydrochloride and fluticasone furoate, in which the raw material fluticasone furoate has good stability in the pH range of 2.5-5.5, and the raw material olodaterol hydrochloride has good stability in the pH range of 2.5-4.0, especially at pH 3.0, the stability is the best, and when the pH value is greater than 4.0, the total impurity content at 60°C for 10 days increases significantly.

[0224] Example 15 Preparation of Indacaterol Maleate Nanosuspension

[0225] Weigh 0.075gEDTA, 4.25gNacl and 0.05g polysorbate 80, add to water for injection and settle to 500ml to prepare buffer. Weigh 39mg indacaterol maleate bulk drug and add to the above-mentioned 50ml buffer, disperser 9000rpm disperses 30min, and the liquid is first homogenized 3 times by high pressure homogenizer, and then homogenized 6 times by 2000bar to obtain homogenized liquid. The homogenized liquid and the remaining buffer are dispersed 30min by disperser 9000rpm to fully mix, and the mixed liquid is filtered through 0.22μm PVDF filter membrane (manufacturer: Cobetter, model: SFM25DLHPVND4522P) to obtain indacaterol maleate single prescription nano suspension

[0226] Example 16 Preparation of Fluticasone Furoate-Indacaterol Maleate Blend Suspension for Inhalation

[0227] 0.075 g EDTA, 4.25 g NaCl and 0.05 g polysorbate 80 were weighed and added to water for injection and the volume was fixed to 500 ml to prepare a buffer solution. 50 ml of the buffer solution was measured, 42.5 mg of fluticasone furoate raw material was weighed and added, and dispersed in a disperser at 9000 rpm for 30 min to obtain a fluticasone furoate suspension.

[0228] 50 ml of buffer was measured again, 39 mg of indacaterol maleate crude drug was weighed and added to the buffer, dispersed at 9000 rpm for 30 min, and then the liquid was homogenized at 1000 bar for 3 cycles by a high pressure homogenizer, and then homogenized at 2000 bar for 6 cycles to obtain a homogenized liquid. The homogenized liquid and the remaining buffer were dispersed at 9000 rpm for 30 min to fully mix, and the mixed liquid was filtered through a 0.22 μm PVDF filter membrane (manufacturer: Cobetter, model: SFM25DLHPVND4522P) to obtain an indacaterol maleate nanosuspension.

[0229] The fluticasone furoate suspension and the indacaterol maleate nanosuspension were dispersed by a disperser at 9000 rpm for 30 minutes to be fully mixed to obtain a fluticasone furoate-indacaterol maleate mixed suspension for inhalation.

[0230] Experimental Example 9: Stability Study of Fluticasone Furoate-Indacaterol Maleate Blend Suspensions at Different pH

[0231] A 0.1 M citric acid-sodium citrate buffer with a pH of 3.0 and a 0.1 M citric acid-sodium citrate buffer with a pH of 6.6 were prepared. The pH of the fluticasone furoate-indacaterol maleate co-suspension was adjusted to 3.5, 4.0, 4.5, 5.0 and 5.5, respectively, using the buffer solution. The suspension was placed in a high temperature influence factor test (60°C for 10 days) to investigate the stability of the preparations in different pH ranges. The results are shown in Table 8.

[0232] Table 8

[0233]

[0234]

[0235] According to Table 8 and Figure 7 It can be seen from the test data that the raw material fluticasone furoate in the fluticasone furoate-indacaterol maleate co-suspension has good stability in the pH range of 3.5-5.5, and there is no significant difference in the single impurities and total impurities under various pH conditions. The raw material indacaterol maleate has good stability in the pH range of 3.5-4.5, especially at pH 3.5, when the stability is the best. When the pH value is greater than 4.5, the total impurity content at 60°C for 10 days increases significantly.

[0236] In summary, the present application provides a suspension or co-suspension comprising a once-daily combination of an ultra-long-acting inhaled steroid and an ultra-long-acting β2 receptor agonist, providing a treatment option for patients who cannot use portable devices such as dry powder inhalers (DPI), metered-dose inhalers (MDI) and soft mist inhalers (SMI), as well as children and critically ill patients.

[0237] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that although the technical solution of the present invention can be modified or replaced by equivalents, it does not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A pharmaceutical preparation comprising a combination of a long-acting inhaled steroid and a long-acting beta2 receptor agonist, characterized in that: include: The long-acting inhaled steroid drug is fluticasone furoate; The long-acting β2 agonist is selected from one or more of vilanterol, olodaterol and indacaterol, wherein the vilanterol is in the form of vilanterol triphenylacetate; the olodaterol is in the form of olodaterol hydrochloride; the indacaterol is in the form of indacaterol maleate; The pharmaceutical preparation further comprises excipients polysorbate 80, EDTA, sodium chloride, and citric acid and sodium citrate buffer; When the long-acting β2 receptor agonist of the pharmaceutical preparation is selected from vilanterol triphenylacetate, the pH value of the pharmaceutical preparation is 3.5-5.0; When the long-acting β2 receptor agonist of the pharmaceutical preparation is selected from olodaterol hydrochloride, the pH value of the pharmaceutical preparation is 2.5-4.0; When the long-acting β2 receptor agonist of the pharmaceutical preparation is selected from indacate maleate, the pH value of the pharmaceutical preparation is 3.5-4.5; The dosage form of the pharmaceutical preparation is a suspension; In the pharmaceutical preparation, at least 90% by volume of the active agent particles have an optical diameter of 7 μm or less; and at least 50% by volume of the active agent particles have an optical diameter of 5 μm or less.

2. The pharmaceutical preparation according to claim 1, which is a nebulized inhalation suspension comprising fluticasone furoate and vilanterol triphenylacetate; wherein the daily inhalation dose of fluticasone furoate is 25-1000 μg, and the daily inhalation dose of vilanterol triphenylacetate is 10-100 μg.

3. The pharmaceutical preparation according to claim 2, characterized in that: The pharmaceutical preparation further comprises sulfobutyl-β-cyclodextrin; the concentration of sulfobutyl-β-cyclodextrin in the pharmaceutical preparation is 5-500 mg / mL.

4. The pharmaceutical preparation according to claim 1, which is an aerosol inhalation suspension comprising fluticasone furoate and olodaterol hydrochloride; wherein the daily inhalation dose of fluticasone furoate is 25-1000 μg, and the daily inhalation dose of olodaterol hydrochloride is 1-100 μg.

5. The pharmaceutical preparation according to claim 1, which is a nebulized inhalation mixed suspension comprising fluticasone furoate and indacaterol maleate; wherein the daily inhalation dose of fluticasone furoate is 25-500 μg, and the daily inhalation dose of indacaterol maleate is 20-200 μg.

6. The method for preparing the pharmaceutical preparation according to any one of claims 1 to 5, characterized in that: The following steps are involved: (1) Add the prescribed amount of excipients to water for injection, stir and dissolve, and adjust the pH with citric acid and sodium citrate buffer to prepare a buffer solution; (2) using a disperser to disperse the long-acting inhaled steroid raw material in the above-mentioned 10% volume buffer solution, stirring with the disperser, and then adding the β2 receptor agonist raw material, and continuing to disperse with the disperser to obtain a dispersion of the two raw materials; (3) mixing the dispersions of the two raw materials with the remaining buffer solution and dispersing them in a disperser to prepare a suspension; (4) The suspension was filled into LDPE bottles to obtain a suspension for inhalation.

7. Use of the pharmaceutical preparation according to any one of claims 1 to 5 in the preparation of drugs for treating respiratory diseases; the respiratory disease is chronic obstructive pulmonary disease.